Compass Therapeutics (NASDAQ:CMPX – Get Free Report) is anticipated to release its earnings data before the market opens on ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 11.90%, which has investors questioning if this is right time to buy.

In this article, we are going to take a look at where Compass Therapeutics, Inc. (NASDAQ:CMPX) stands against the other smid-cap stocks. As the name suggests, smid-cap stocks have a valuation ...

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Ratings reports. Two analysts ...

Financially, CMPX has a market cap of $423mn, a cash balance of $135mn, and a cash runway of 10-11 quarters, ensuring sufficient funding. The BTC market is small and competitive, with existing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Compass Therapeutics, Inc. (CMPX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

In this article, we are going to take a look at where Compass Therapeutics, Inc. (NASDAQ:CMPX) stands against the other biotech stocks. No matter the market environment, you’ll always find ...